← Eichor
Study identifier: NCT06968559 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Effect of Early Dexamethasone on Major Complications and All-cause Mortality in Severe Burns

Condition: Severe Burns  ·  Sponsor: Nantes University Hospital

PhasePhase 3
Planned participants478
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

Burns affect more than 11 million people worldwide each year. These injuries are responsible for severe morbidity resulting in a high societal burden and account for more than 180,000 yearly deaths especially in low- and middle-income countries. Major burns induce an important local and systemic inflammatory response that may be overwhelmed. This inflammation is a physiological phenomenon that favours the healing of tissues. However, the overproduction of inflammatory mediators might lead to an exacerbated Systemic Inflammatory Response Syndrome (SIRS). Recently the total body surface area (TBSA) burned has shown to be well correlated to persistent elevation of pro-inflammatory mediators (such as IL-6). This SIRS, in turn, contributes to the enhanced risk of sepsis, acute respiratory distress syndromes (ARDS) and organ failures in general such as acute kidney injuries (AKI), most of those occurring within the first week of admission. Corticosteroids (CS) have already proven their effectiveness against SIRS-induced organ dysfunction or mortality in acute medicine notably in septic shock, polytraumatized patients and more recently in the treatment of viral or non-viral ARDS without increasing the risk of secondary bacterial complications or significant side effects . Indeed the recent SCCM Guidelines clearly advocate for the use of CS in severe community-acquired pneumonia, septic shock and ARDS. The investigators recently performed a large multicenter, double-blinded randomi…

This description comes directly from the study's public registry record.

Talk to the study team

Karim ASHENOUNE, MD, PhD  ·  +33 (0)2 53 482 835  ·  karim.asehnoune@chu-nantes.fr

Alexandre BOURDIOL, PH  ·  +33 (0)2 53 482 217  ·  alexandre.bourdiol@chu-nantes.fr

Always discuss trial participation with your own doctor first.

Locations (10)

CHU ToursChambray-lès-Tours, FranceNot Yet Recruiting
CHU LilleLille, FranceNot Yet Recruiting
CHU de LyonLyon, FranceNot Yet Recruiting
Aphm Hopital La TimoneMarseille, FranceNot Yet Recruiting
CHR MetzMetz, FranceNot Yet Recruiting
CHU MontpellierMontpellier, FranceNot Yet Recruiting
Chu NantesNantes, FranceRecruiting
HU Saint-Louis LariboisièreParis, FranceNot Yet Recruiting
CHU BordeauxPessac, FranceNot Yet Recruiting
CHU ToulouseToulouse, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06968559